ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01FF03 | BioTech | Durvalumab - 500mg/10ml | 11729 | 74419/1 | IMFINZI | 500mg/10ml | 1x10ml | Injectable solution | Infusion | Omnipharma | AstraZeneca AB | USA | 227,939,689 L.L | 2.44 | E2 | AstraZeneca UK Ltd | UK | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01FF03 | BioTech | Durvalumab - 500mg/10ml | 10033 | 74419/1 | IMFINZI | 500mg/10ml | 1x10ml | Injectable solution | Infusion | Omnipharma | Catalent Indiana, LLC | USA | 227,939,689 L.L | 2.44 | E2 | AstraZeneca UK Ltd | UK | 2/5/2024 | 0 |
L01FF03 | BioTech | Durvalumab - 500mg/10ml | 10033/388 | 74419/1 | IMFINZI | 500mg/10ml | 1x10ml | Injectable solution | Infusion | Omnipharma | Catalent Indiana, LLC | USA | L.L | 2.44 | E2 | AstraZeneca UK Ltd | UK | 2/5/2024 |